News items related to: Medicine Equality Now!
-
New Analysis Exposes Path to Affordable Lenacapavir for HIV Prevention
Lenacapavir, administered just twice a year, has been shown to reduce HIV transmission to nearly zero. However, the drug’s high...
-
An Earsplitting Silence: Pharma Makes Billions, Says Nothing About the Current Global Funding Crisis for HIV, Tuberculosis and Other Life-Threatening Illnesses
“It is shocking that the crisis facing the global HIV community has been met with such a resounding silence from...
-
‘A Matter of Life and Death’: Civil Society Groups Fight for Affordable DR-TB Treatment
“As the patent holder, Otsuka has prevented access to improved TB treatment due to its exorbitant prices. On World TB...
-
TNP+ is Successfully Opposing Big Pharma’s Hepatitis C Drug Monopoly
This win comes after years of campaigning by the AIDS Access Foundation (AAF) and the Thai Network of People Living...
-
Lenacapavir Patent Faces Opposition at the Eurasian Patent Office
“If Gilead Science’s patent application regarding Lenacapavir is granted, the patent will represent another significant barrier to the affordable access...
-
Major Win: First Batch of Dolutegravir Arrives in Colombia Under a Compulsory License
The World Health Organization (WHO) recommends dolutegravir as the first- and second-line treatment for all population groups. In Colombia, access...
-
Empowering Africa’s Pharmaceutical Future: Local Manufacturing and IP Reform as Game-Changers
The African pharmaceutical market is on the rise, with its value soaring to $25 billion in 2022 and projected to...
-
ITPC-EECA Challenges Patents on core DR-TB Drug Pretomanid, Urging Eurasian Patent Office to Protect Access
According to WHO, 400,000 people developed DR-TB in 2023, yet only 44% (175, 923) of them were treated for it....
-
MMA Partner VNP+ Opposes Patent Application Which Would Limit Access to Long-Acting Cabotegravir
Vietnam’s Network of People Living With HIV (VNP+), a Make Medicines Affordable (MMA) partner, is working to improve access to, and affordability...
-
Thai HIV Advocacy Group Challenges Gilead’s and Janssen’s Patent Extension Bid, Citing Evergreening Tactics
The Thai Network of People Living with HIV/AIDS (TNP+) filed an opposition to a patent application filed by the U.S.-based pharmaceutical giant...
-
People’s Resolution: A Roadmap to Protect the Right to Life in a Failed Multilateral Order
We, as members of communities, civil society and activists affected by epidemics, call for a plan of action to end...
-
J & J’s Deal With the Global Drug Facility Disguises the Continued Issue with Access to Bedaquiline to Treat Drug-Resistant Tuberculosis
“This deal is big step backwards for global public health – it allows J & J to keep selling higher-priced...